WIXLIB

postdoctoral trainees and (3) foster multidisciplinary mentored relationships and collaborationsbetween diverse faculty and trainees from Washington University and INCAN, as well as createopportunities for future research projects. VIETNAM: Dr. Craig Allred is collaborating with Dr. Richard Love at OSU on a study that justfinished accruing participants and is focused on women with receptor-positive breast cancer inVietnam. Women were also recruited in the Philippines and China.The Barbara Ann Karmanos Cancer Institute – Wayne State UniversityInstitute-wide activities and consortia JAPAN: Working with the Educational Outreach and International Programs and the Graduate School at the Wayne State University, the Cancer Biology Graduate Program in the Departmentof Oncology has initiated a formalized collaborative program with Okayama University inOkayama, Japan for short-term exchanges (1-2 semesters) of graduate students in CancerBiology. Although Dr. Manohar Ratnam has already hosted a PhD student from OkayamaUniversity from June-December 2013, the formalized collaboration between the universities willbegin when Dr. Larry Matherly travels to Okayama University in early February 2014.JAPAN and EUROPE: Dr. Leonard Lipovich is an Assistant Professor, Center for MolecularMedicine and Genetics, and is the sole person in the entire State of Michigan participating inboth FANTOM and ENCODE. As a full member of the FANTOM Consortium (FunctionalAnnotation of Mammalian Genomes), based at RIKEN, Yokohama, Japan, since 2004, Dr.Lipovich studies cancer long non-coding RNAs (lncRNAs) by direct single-molecule sequencing.The overall goal of FANTOM is to quantitate the entire human promoterome at single-baseresolution using Helicos RNAseq technology. Since 2011, Dr. Lipovich is also a funded memberof the ENCODE (Encyclopedia of DNA Elements), the world's pre-eminent genomicscollaboration. This is the direct successor to the original Human Genome Project. Scientistsfrom the US, UK, Spain, and Japan participate in this project. His role in ENCODE is to showthat primate-specific lncRNAs are functional in human breast cancer. Dr. Mary Ann Kosir of KCIis a collaborator on this project. .Dr. Lipovich’s work within and outside of these consortia hasgarnered international recognition, including; as an invited opening-session speaker, RegulatoryRNA Workshop, Baeza, Spain, Nov 2013; invited Visiting Faculty Fellow, University of NewSouth Wales, Australia, Oct 2013; invited speaker, RNA in Cancer Meeting, Univ. of Heidelberg(Germany) (June 2014), chair, The Royal Society Int'l Scientific Meeting on LncRNA (London,UK, Sep 2015), and solicited invited chair, Keystone Symposium on LncRNA Evolution andFunction (Keystone, Colorado, Mar 2015).QATAR: Dr. Ramzi Mohammad, Professor of Oncology, is working to establish a state-of-theart research center in Doha, Qatar (the gulf area) with an anticipated completion date of early2015. This endeavor includes creation of a cancer center and a bio-bank. Dr. Mohammad isworking to develop a strong relationship between Qatar and Karmanos Cancer Institute / WayneState University on several levels including research collaboration, teaching, and training.Towards this end, several KCI faculty will be visiting the medical center in Qatar in the upcomingyear including Drs. Philip Philip and Lawrence Lum. Additionally, several Karmanos CancerInstitute investigators (Drs. Azmi, Bollig-Fischer, Dou, and Wei) have submitted collaborativegrants with faculty from Qatar.WORLDWIDE: The Metropolitan Detroit Cancer Surveillance System (MDCSS), for whichKarmanos Cancer Institute / Wayne State University holds the contract (N01 PC-2010-00029,PI: Ann Schwartz, PhD, MPH) and provides funding, is a founding member of the NCISurveillance, Epidemiology and End Results (SEER) Program. The MDCSS is also a member inthe North American Association of Central Cancer Registries (NAACCR), a uniform standards-Page 6 of 134

setting professional organization including members from the United States and Canada. TheMDCSS recently contributed to Cancer Incidence on Five Continents and InternationalIncidence of Childhood Cancer, both publications of the World Health Organization (WHO)International Agency for Research on Cancer (IARC).Investigator-initiated activities ARGENTINA and SPAIN: Dr. Robert Mathog is Professor and Chair of Otolaryngology andhas been involved in international activities since 1986 including the “Sisters Program’. The“Sisters Program” is an international exchange program in which the Department ofOtolaryngology – Head & Neck Surgery at Wayne State University shares information withinternational colleagues (residents and/or fellows) who rotate for a short-term through thedepartment. Arrangements have been established with the Department of Otolaryngologybetween the School of Medicine, Buenos Aires, Argentina; the School of Medicine, Pamplona,Spain; the School of Medicine of Cordoba, Argentina; Austral University School of Medicine,Buenos Aires; Fundacion Arauz, Buenos Aires; ASALFA, Buenos Aires; SAV SociedadArgentina de la Voz, Buenos Aires; and the University of Aconcagua, School of Medicine,Mendoza, Argentina. Wayne State University faculty are also invited from time to time to visitand teach at one of the participating institutions. AUSTRALIA, BRAZIL, CANADA, EGYPT, GERMANY and SOUTH AFRICA: Dr.Bonnie Sloane is a Distinguished Professor and Chair of Pharmacology and has hadinternational collaborations for more than 30 years. She has hosted dozens of students(undergraduate and graduate), postdoctoral associates and visiting scientists from all over theworld. Current activities include; (1) Dr. Sloane is hosting for eight months a visiting doctoralstudent, Ms. Suelem Demuner Ramalho, from the Universidade Federal de São Carlos, Brazil.Ms. Ramalho is testing the ability of cysteine protease inhibitors (purified from plants) inreducing progression of our 3D/4D breast cancer models, (2) Dr. Sloane has continuingcollaborative interactions with Egyptian collaborators (Cairo University -- Dr. Mona MostafaMohamed; Ain Shams University – Dr. Mohamed El-Shinawi) on cytokines in macrophages aspossible therapeutic targets in inflammatory breast cancer, (3) Dr. Sloane is a consultant on anNHRMC (Australian) grant on the endogenous cysteine protease inhibitor stefin A with Dr.Belinda Parker, a collaborator from Trobe University (Melbourne, Australia). She hosted Dr.Parker’s Ph.D. student for studies on cathepsin B in bone metastasis, featured on the cover ofCancer Research, and is a mentor on Dr. Parker’s postdoctoral student’s application for a DoDfellowship for Dr. Laura Edgington to continue studies on bone metastasis, (4) As a collaboratorof Dr. Thomas Reinheckel’s of Albert Ludwigs University, Freiburg, Germany, Dr. Sloane servedas an external examiner for the Ph.D. of his student, Dr. Fee Bengsch, part of her Ph.D.research was conducted in Dr. Sloane’s laboratory, (5) In October of 2013 Dr. Sloane was oneof the faculty presenting two imaging workshops for student (graduate and postdoctoral) at theUniversity of Cape Town (South Africa) in conjunction with the 8th General Meeting of theInternational Proteolysis Society, and (6) Closer to home, she has a continuing collaborationwith Drs. Lisa Porter and Dora Cavallo-Medved of the Department of Biological Sciences at theUniversity of Windsor on mechanisms underlying breast cancer progression. CANADA: Dr. Nebojsa Duric is a Professor of Oncology and is a co-founder of theInternational Imaging Center, established in 2011. This center is a joint effort between WayneState University and Dr. Roman Maev of the University of Windsor (Windsor, Ontario, Canada).The center’s goal is to stimulate cross-border collaborations between Canada and the USA witha focus on imaging technologies. Additionally, the founders anticipate promoting collaborationswith other countries in the future.Page 7 of 134

CANADA: Dr. Lisa Porter, Associate Professor of Biological Sciences (University of Windsor),and Dr. Dora Cavallo-Medved, Adjunct Assistant Professor in the Pharmacology (Wayne StateUniversity), direct the Windsor Cancer Research Group (WCRG). The WCRG is an assemblyof researchers and clinicians working together to create teams to strengthen our local cancerresearch programs, bridge collaborations with neighboring cancer centers (Karmanos CancerInstitute) and universities and enhance the reputation and connections with the Windsor/EssexOntario community. CANADA: Dr. Jeffrey Zonder is an Associate Professor of Oncology and anticipates openingan investigator-initiated multi-center amyloidosis study that will include Princess MargaretHospital in Toronto, Canada as a participating site. CANADA, CZECH REPUBLIC, and ITALY: Dr. Q. Ping Dou is a Professor of Oncologyand works on several international projects including: (1) with Prof. Tak-Hang (Bill) Chan, McGillUniversity, Canada, and The Hong Kong Polytechnic University in China on novel green teapolyphenol-based proteasome inhibitors as anticancer drugs, (2) with Profs. Boris Cvek andZdenek Dvorak, Palacky University, Czech Republic, on reposition of the old drug disulfaram incancer treatment, (3) with Prof. Dolores Fregona, University of Padova, Italy, on development ofnovel gold-containing complexes as potential proteasome inhibitors and anticancer drugs, and(4) with Prof. Arun Seth of University of Toronto in Canada on breast cancer-associated gene 2. CANADA, NEW ZEALAND, AUSTRALIA, and PUERTO RICO: Dr. Jeffrey Taub(Division Chief, Oncology and Professor of Pediatrics at Wayne State University / KarmanosCancer Institute) is the study chair of the Children’s Oncology Group (COG) AAML0431 phaseIII clinical trial, “Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) andMyelodysplastic syndrome (MDS) Under the Age of 4 Years” which is the largest studydesigned to treat children with Down Syndrome and leukemia and is currently institutionalreview board (IRB) approved at 150 institutions, including 14 institutions in Canada, one in NewZealand, one in Puerto Rico and two in Australia. Leukemia samples from these patients arebeing sent to Children’s Hospital of Michigan/Karmanos Cancer Institute as the coordinatingreference laboratory for the correlative biology studies of the clinical trial. CHINA: Dr. Q. Ping Dou, Professor of Oncology, works on several projects with researchers inChina including: (1) with Prof. Caifeng Bi, Ocean University of China, on bioinorganic chemistry,anticancer drug discovery, (2) with Prof. Jinbao Liu, Guangzhou Medical University, on Chinesemedicine, natural proteasome inhibitors, and (3) with Prof. Bing Yan, Shandong University, oncopper, nanoparticles, chemistry-biology combination approach for anticancer drug discovery.He also trains and co-mentors PhD students and research scientists from the institutesmentioned above. CHINA: Dr. Yubin Ge is an Assistant Professor of Oncology and is collaborating withcolleagues (Drs. Yingjie Guo and Wei Kong) at the College of Life Science, Jilin University,Changchun, P.R. China on pancreatic cancer research and pediatric acute leukemia research. CHINA: Dr. Jiani Hu is an Associate Professor of Radiology and participates in a number ofinternational collaborations to explore the potential of recently developed MRI techniques indiagnosis, prognosis and treatment of various cancers including: (1) with Changzhou FirstHospital in Changzhou investigating renal cancer, (2) with Renji Hospital studying bladder andprostate cancer, (3) with Southwest Hospital in Chongqing investigating breast and liver cancer,(4) with Zhejiang Province Chinese Medical Hospital in Hangzhou studying breast cancer, (5)with The First Affiliated Hospital of Dalian Medical University in Dalian studying ovarian anduterus cancer, and (6) with The Affiliated Union Hospital of Tongji Medical School in Wuhaninvestigating pancreatic cancer.Page 8 of 134

CHINA: Dr. Chunying Li is an Assistant Professor of Biochemistry & Molecular Biology andcollaborates with Drs. Jing Liu and Peijie Chen at Shanghai University of Sport, Shanghai,China. The overall goal of their collaboration is to investigate the effects and mechanisms oftraditional Chinese martial arts (such as Tai Chi, Qi Gong, etc.) on health promotion andrehabilitation in patients of certain diseases (such as lung cancer patients, chronic low back painpatients), aged populations with neurodegenerative disorders, and sex and age-matchedhealthy controls.CHINA: Dr. Douglas Ruden, Associate Professor and Director of Epigenomics at Institute ofEnvironmental Health Sciences collaborates with Dr. Qi Niu at the Department of MedicalOncology, No. 309 PLA Hospital, Beijing, PR China. The focus of this collaboration is to findinexpensive ways to improve cisplatin chemotherapy treatments of a variety of cancers. Thisproject was supported by the Scientific Research Foundation for the Returned OverseasChinese Scholars, China State Education Ministry (No. 2007–1108) to Dr. Niu and NationalInstitutes of Health grant ES012933 to Dr. Ruden.CHINA: Dr. Zeng-Quan Yang, Assistant Professor in Oncology, is collaborating with threeuniversities (Shantou University Medical College, Norman Bethune College of Medicine of JilinUniversity and Jiangsu Normal University) in China, to investigate the fundamental mechanismby which dysregulation of the histone demethylase, GASC1 (Gene Amplified in Squamous CellCarcinoma 1, also known as JMJD2C and KDM4C), contributes to tumorigenesis, and toestablish it as a novel therapeutic target for human esophageal, breast and prostate cancers. Tothis end, one visiting scientist and one visiting PhD student from the Norman Bethune College ofMedicine of Jilin University and the Jiangsu Normal University are currently working in hislaboratory at Karmanos.CHINA and NETHERLANDS: Dr. Kang Chen, Assistant Professor in Obstetrics andGynecology, studies the immune pathogenesis of infection and immunodeficiency and theregulation of host anti-tumor immune responses, with a focus on host humoral immunity againsttumors. He has international collaborations with scientists in the Netherlands and China on invivo imaging of immune cells in cancer and autoimmunity. His collaborators are funded by theEuropean Research Council (ERC) and the Natural Science Foundation of China (NFSC). Hehas also been involved in activities in the NGO Committee on Human Settlements, inconsultative relationship with the United Nations Economic and Social Council (ECOSOC) andin partnership with the UN Human Settlements Programme (UN-HABITAT) pertaining tosustainable urbanization and infectious disease prevention in urban settings.GERMANY: Dr. Maik Hüttemann, an Associate Professor in the Center for Molecular Medicineand Genetics, actively collaborates with Prof. Dr. Norbert Weissmann of the University

the NCI Center for Global Health for information on international activities. This is an ongoing data- . Dr. Graham Colditz is an epidemiologist and internationally known leader . that primate-specific lncRNAs are functional in human breast cancer. Dr. M